What side effects are most commonly linked to Cosentyx (secukinumab) in psoriasis?
Cosentyx (secukinumab) is an IL-17A inhibitor. In psoriasis, this mechanism lines up with a side-effect pattern seen across IL-17–targeting biologics: infections (especially mucocutaneous candida-type infections) and upper respiratory or flu-like illness are among the more consistently reported adverse events. Some patients also report injection-site reactions and gastrointestinal symptoms. [1]
How does Cosentyx’s infection risk compare with TNF inhibitors?
Compared with TNF blockers, IL-17 inhibition tends to show a different emphasis in infections. TNF inhibitors commonly carry a broader warning profile for serious infections (including tuberculosis risk), whereas IL-17 inhibitors are more strongly associated with fungal infections such as oral/thrush or other candida-related events. In practice, both drug classes require infection screening and monitoring, but the “type” of infection signal often differs. [1]
How does Cosentyx compare with other IL-17 drugs (and what patients notice)?
Cosentyx is one IL-17A option in psoriasis care, and its side-effect profile is usually compared with other IL-17 pathway agents. Across IL-17 therapies, candida/mucocutaneous fungal infections and upper respiratory infections are recurring themes, while injection-site reactions are also typical for monoclonal antibody biologics. Differences between individual IL-17 products can show up in how often certain adverse events occur, but the overall pattern is broadly similar because they target the same pathway. [1]
What about IL-23 inhibitors and ustekinumab—are the side effects different?
IL-23 inhibitors and ustekinumab (which targets IL-12/23) generally have an adverse-event profile that still includes infections, but the fungal-infection emphasis seen with IL-17 blockade is typically less prominent than with IL-17 inhibitors. Clinicians often highlight that IL-23 and ustekinumab can have a different balance of risks than IL-17 agents, which is one reason switching classes is considered when a patient has recurrent infections or specific concerns about fungal disease. [1]
What side effects lead to switching from Cosentyx to another psoriasis treatment?
Patients and clinicians are most likely to consider switching if adverse events are persistent or severe, such as recurrent or significant infections, bothersome injection-site reactions, or new/worsening fungal infections. Because the mechanism differs across drug classes, switching from Cosentyx (IL-17A) to an IL-23 inhibitor, TNF inhibitor, or another non–IL-17 option is sometimes used to change the side-effect risk pattern. [1]
Are there safety differences between biologics and oral/systemic psoriasis drugs?
Yes. Biologics like Cosentyx typically have a side-effect pattern dominated by infection risk and hypersensitivity/injection-site issues. Many oral systemic drugs can carry different risks (for example, drug-specific liver, blood count, metabolic, or teratogenic concerns depending on the medication). So even when overall tolerability is good, patients may see a tradeoff: biologics usually avoid many of the systemic lab-monitoring burdens that come with some oral options, but they still require infection vigilance. [1]
What should patients ask their clinician before starting (or continuing) Cosentyx?
Patients commonly ask about:
- Whether they need screening for infection risks before treatment
- Their personal history of recurrent infections or fungal issues
- What symptoms suggest a candida or serious infection that should prompt stopping and contacting a clinician
- How switching options differ if adverse events occur
These questions tie directly to the adverse-event profile associated with IL-17A inhibition. [1]
---
Sources:
[1] https://www.cosentyx.com/safety-and-side-effects